Charting bioethical frontiers: China’s human organoid guidelines in a global context

The rapid progress of human organoid toolkits presents unprecedented opportunities in disease modeling, drug discovery, and personalized therapy, alongside profound bioethical challenges and concerns.On April 29th, 2025, China's National Science and Technology Ethics Committee (Life Science Ethics Subcommittee) issued the Human Organoid Research Ethical Guidelines [1], establishing the world's first comprehensive governance framework, especially focusing on brain organoids, embryo models, and chimeric research.This Guidelines represent a pioneering governance model in emerging biotechnology.This commentary offers an in-depth analysis to examine the policy's innovative three-tiered structure, contrast it with current global regulatory standards, evaluate its domestic impacts as well as potential implications for international biotechnology governance, and provide recommendations for future directions.